Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.73 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 3/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27957526 | 0.87 | METAP2 (0.56) | METAP2TRPA1TRPM8S1PR1NOS1 | |
| SCHEMBL19922226 | 0.86 | CLK1 (0.68) | METAP2TRPA1TRPM8S1PR1ROCK2 | |
| SCHEMBL23136093 | 0.85 | METAP2 (0.54) | METAP2TRPA1TRPM8S1PR1NOS1 | |
| SCHEMBL1273777 | 0.85 | METAP2 (1.00) | METAP2TRPA1TRPM8NOS1MEN1 | |
| SCHEMBL29937203 | 0.85 | METAP2 (1.00) | METAP2TRPA1TRPM8NOS1MEN1 | |
| SCHEMBL25083949 | 0.82 | METAP2 (0.51) | METAP2TRPA1TRPM8S1PR1NOS1 | |
| SCHEMBL25480129 | 0.81 | METAP2 (0.50) | METAP2TRPA1TRPM8S1PR1NOS1 | |
| SCHEMBL23136097 | 0.81 | METAP2 (0.50) | METAP2TRPA1TRPM8S1PR1NOS1 | |
| SCHEMBL762038 | 0.81 | IDH1 (0.55) | METAP2TRPA1TRPM8NOS1ROCK2 | |
| SCHEMBL19922168 | 0.81 | TRPA1 (0.62) | METAP2TRPA1TRPM8S1PR1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119020039-A | Long-life chip cleaning liquid for stably etching TiN, preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| WO-2009009411-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | claimed |
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2025-06-19 | — | — | US | disclosed |
| CN-120025297-A | Mycobacterium membrane protein MmpL inhibitor, pharmaceutical composition and application thereof | 和径医药科技（上海）有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-115947690-B | Preparation method of indazole molecular building block and application of indazole molecular building block in drug synthesis | 安徽医科大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-119020039-A | Long-life chip cleaning liquid for stably etching TiN, preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024233776-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024012570-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 西藏海思科制药有限公司 | 2024-01-18 | — | — | WO | disclosed |
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2010107742-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| WO-2009039248-A2 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | STANFORD UNIVERSITY (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039246-A2 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | STANFORD UNIVERSITY (US) | 2009-03-26 | — | — | WO | disclosed |
| US-3931220-A | FUNGICIDE, BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | METAP2 400/4885TRPA1 3552/4885TRPM8 4063/4885 |
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | IP6K1, HIPK1, IP6K3 | METAP2 3652/4885TRPA1 4864/4885TRPM8 4748/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | METAP2 400/4885TRPA1 3552/4885TRPM8 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.